NCT07701161 Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
| NCT ID | NCT07701161 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Neurogen Biomarking LLC |
| Condition | Alzheimer s Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-01-13 |
| Primary Completion | 2026-03-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-01-13 with a primary completion date of 2026-03-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Eligibility Criteria
Inclusion Criteria: * AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed Exclusion Criteria: * Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Contact & Investigator
Rany Aburashed
PRINCIPAL INVESTIGATOR
Insight Health Systems
Frequently Asked Questions
Who can join the NCT07701161 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 90 Years, studying Alzheimer s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07701161 currently recruiting?
Yes, NCT07701161 is actively recruiting participants. Contact the research team at ansam@neurogenbiomarking.com for enrollment information.
Where is the NCT07701161 trial being conducted?
This trial is being conducted at Chicago, United States, Dearborn, United States, Flint, United States, Owosso, United States and 1 additional location.
Who is sponsoring the NCT07701161 clinical trial?
NCT07701161 is sponsored by Neurogen Biomarking LLC. The principal investigator is Rany Aburashed at Insight Health Systems. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.